ARA-290 Dosage: Doses Studied, Units and Chart
What doses of ARA-290 have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 9 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- ~2 min
- plasma (route not stated in abstract), in people · Pharmacology & therapeutics 2015, PMID 25728128
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 1, 4 or 8 mg/day (cibinetide = ARA 290) | 28 days | Human RCTn = 64 | Investigative ophthalmology & visual science 2017, PMID 28475703 |
| 4 mg | daily · subcutaneous, self-administered · 28 days, followed for an additional month | Human controlled trial | Molecular medicine 2015, PMID 25387363 |
| 2 mg | single dose | Human RCTn = 36 | European neuropsychopharmacology 2015, PMID 26431906 |
| 2 mg (n = 12) vs placebo (n = 10) | three times weekly · intravenous · 4 weeks | Human RCTn = 22 | Molecular medicine 2012, PMID 23168581 |
| 4 mg/day | subcutaneous, self-administered · 12 weeks | Human uncontrolled trialn = 9 | Journal of clinical medicine 2020, PMID 32674280 |
| 30ug/kg | daily · subcutaneous | Animal · mouse (genetic diabetes, db/db) (not a human result) | Biochimica et biophysica acta. Molecular basis of disease 2018, PMID 29223734 |
| 35, 70 ug/kg | once daily · intraperitoneal | Animal · rat (not a human result) | Journal of neuroimmunology 2014, PMID 24518674 |
| 30 or 120 ug/kg | daily · intraperitoneal | Animal · rat (not a human result) | Neuroscience 2013, PMID 23262243 |
| 30 ug/kg | five doses at 2-day intervals then once per week · intraperitoneal | Animal · rat and mouse (including beta-common receptor knockout mice) (not a human result)n = 8 | Anesthesiology 2011, PMID 21873879 |
Before anyone considers it
- ARA-290 is Not FDA approved · research chemical; research-chemical versions are not the approved drug.
- Compounded and research-chemical versions are not the approved product and are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Common questions
Is ARA-290 FDA approved?
ARA-290 is Not FDA approved · research chemical. Products sold as research chemicals are not the approved drug and are not checked by the FDA.
More on ARA-290
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.Investigative ophthalmology & visual science · 2017PMID 28475703Accessed 2 Oct 2026
- 4ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Molecular medicine (Cambridge, Mass.) · 2015PMID 25387363Accessed 2 Oct 2026
- 5Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015PMID 26431906Accessed 2 Oct 2026
- 6Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.Molecular medicine (Cambridge, Mass.) · 2012PMID 23168581Accessed 2 Oct 2026
- 7A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.Journal of clinical medicine · 2020PMID 32674280Accessed 2 Oct 2026
- 8Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.Biochimica et biophysica acta. Molecular basis of disease · 2018PMID 29223734Accessed 2 Oct 2026
- 9Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat.Journal of neuroimmunology · 2014PMID 24518674Accessed 2 Oct 2026
- 10The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model.Neuroscience · 2013PMID 23262243Accessed 2 Oct 2026
- 11ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.Anesthesiology · 2011PMID 21873879Accessed 2 Oct 2026
- 12Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.Pharmacology & therapeutics · 2015PMID 25728128Accessed 2 Oct 2026
Found an error? Report a correction.